AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...
AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration ...
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.